The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Gilead Sciences (I)
Research Funding - Juno Therapeutics
Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).
 
Jennifer M. Specht
Honoraria - Daiichi Sankyo; Genomic Health; Nektar
Consulting or Advisory Role - Daiichi Sankyo; Genomic Health; Nektar
Research Funding - Cascadian Therapeutics (Inst); Genentech (Inst); Merck (Inst); Minerva Biotechnologies (Inst); Myriad Pharmaceuticals (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Seagen (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Nektar
 
David G. Maloney
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; Celgene; Genentech/Roche; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Legend Biotech; MorphoSys; Novartis; Pharmacyclics
Consulting or Advisory Role - A2 Biotherapeutics
Research Funding - Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on 4 provisional patents.
 
Cecilia Yeung
Research Funding - Minerva Biotechnologies (Inst)
 
Vicky Wu
No Relationships to Disclose
 
Cynthia Bamdad
Employment - Minerva Biotechnologies
Leadership - Minerva Biotechnologies
Stock and Other Ownership Interests - Minerva Biotechnologies
Patents, Royalties, Other Intellectual Property - Minerva Biotechnologies